TABLE 5.

Controlled Studies of Testosterone Supplementation in Cognitively Impaired Older Men with Normal Testosterone

Authors, Year	N	Mean Age (Range) If Reported	Method of T Measurement	Baseline T Level (Cognitive Impairment)	Cognitive Measures*	Supplementation Method	Significant Conclusions
Cherrier et al, 2005	32	76 (63–85)	TT	“Low-normal” (Alzheimer disease or mild cognitive impairment)	MEM 4, 19 VS 3, 7 ATT 3, 5	T enanthate intramuscularly 100 mg weekly for 6 weeks	Improvement in MEM 3, 19 and VS 3, 7 with T
Fukai et al, 2010	11	81	Fasting morning TT	Not reported (mild to moderate cognitive impairment)	GLOB 1, 3	T undecanoate orally 40 mg/day for 6 months	Improvement in GLOB 1, 3 with T
Lu et al, 2006	47	70	TT, DHT, FT	Not reported (Alzheimer disease)	MEM 7 VS 2, 3, 14	T gel 75 mg/day for 24 weeks	Less decline in T group versus placebo in VS 14

^*Table 1 explains the abbreviated cognitive domains and the numbered cognitive tests.

T = testosterone. TT = total testosterone. AD = Alzheimer disease. DHT = dihydrotestosterone. FT = free testosterone.